SVR | No SVR | Uni-variate | Multi-variate | Multivariate | |
---|---|---|---|---|---|
n = 64 | n = 54 | p-value | p-value | Odds-ratio (95% CI) | |
Age [years] | 40 (27 - 54) | 41 (27 - 48) | 0.566 | - | - |
Male sex [%] | 75 | 78 | 0.662 | - | - |
Transm. risk IVDU [%] | 20 | 30 | 0.709 | - | - |
HCV GT 1 or 4 [%] | 50 | 76 | 0.002 | 0.001 | 0.2 (0.1 - 0.5) |
HCVRNA ≥ 5 × 105 IU/ml[%] | 42 | 63 | 0.014 | 0.009 | 0.3 (0.1 - 0.7) |
ALT [IU/l] | 63 (19 - 190) | 80 (25 - 250) | 0.368 | - | - |
Weight adapted RBV [%] | 88 | 73 | 0.237 | - | - |
Tx duration 48 wks [%] | 47 | 27 | 0.309 | - | - |
Enrollment period [%] | |||||
2002 - 2004 | 56 | 67 | 0.253 | - | - |
2005 - 2007 | 44 | 32 | |||
Treatment arm [%] | |||||
B (no HAART) | 44 | 39 | |||
C1 (NRTI-cont.) | 33 | 52 | 0.047 | 0.025 | 0.3 (0.1 - 0.9)* |
C2 (NRTI free) | 23 | 9 | |||
HIV-RNA [copies/ml, log 10 ] | 1.7 (1.7 - 4.8) | 1.7 (1.7 - 4.8) | 0.372 | - | |
CD4-cellcount | |||||
[/μl] | 487 (236 - 1042) | 542 (222 - 831) | 0.828 | - | |
[%] | 27 (15 - 41) | 26 (12 - 41) | 0.364 | - | |
Anemia [%] | |||||
Grade 1/2 | 11 | 11 | 1.000 | . | |
Grade 3/4 | - | - | |||
Leucopenia [%] | |||||
Grade 1/2 | 47 | 41 | 0.578 | - | |
Grade 3/4 | 9 | 7 | 0.753 | ||
Thrombocytopenia [%] | |||||
Grade 1/2 | 47 | 43 | 0.712 | - | |
Grade 3/4 | 5 | 6 | 1.000 | ||
Clinical adverse events [%] | |||||
Grade 1/2 | 67 | 69 | 1.000 | - | |
Grade 3/4 | 11 | 13 | 0.781 | ||
Dose reduction PegIFN [%] | 11 | 9 | 1.000 | ||
Dose reduction RBV [%] | 13 | 20 | 0.215 | - | |
Treatm. discont. AEs [%] | 5 | 24 | 0.003 | 0.004 | 0.1 (0 - 0.5) |